LAPTM5 and plasma cell myeloma: However, a large-scale screening of tumor cell lines found that LAPTM5 mRNA levels were generally reduced in various cancer cell lines, including esophageal squamous (ESCC), prostate, undifferentiated thyroid, neck, hepatocellular carcinoma (HCC), breast, glioma, renal cell, endometrial, ovarian, bladder, gallbladder, small cell lung (SCLC), gastric, myeloma, non-small cell lung cancer (NSCLC), and pancreatic cancer [7].